【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌

智通财经2025-06-26

【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌的最新2期临床试验数据】智通财经APP讯，和誉-B(02256.HK)发布公告，2025年6月26日，上海和誉生物医药科技有限公司(“和誉医药”)宣布将在2025 年欧洲肿瘤内科学会胃肠道肿瘤大会(“2025年ESMO GI会议”)上汇报依帕戈替尼(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2546227969?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-26 08:26","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2546227969","market":"us","top_or_hot":-1,"title":"【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌","media":"智通财经","content":"<div>\n<p>【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌的最新2期临床试验数据】智通财经APP讯，和誉-B(02256.HK)发布公告，2025年6月26日，上海和誉生物医药科技有限公司(“和誉医药”)宣布将在2025 \n\n年欧洲肿瘤内科学会胃肠道肿瘤大会(“2025年ESMO \n\nGI会议”)上汇报依帕戈替尼(...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-26 08:26 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌的最新2期临床试验数据】智通财经APP讯，和誉-B(02256.HK)发布公告，2025年6月26日，上海和誉生物医药科技有限公司(“和誉医药”)宣布将在2025 \n\n年欧洲肿瘤内科学会胃肠道肿瘤大会(“2025年ESMO \n\nGI会议”)上汇报依帕戈替尼(...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2546227969","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546227969","pubTimestamp":1750897582,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌的最新2期临床试验数据】智通财经APP讯，和誉-B(02256.HK)发布公告，","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","161726":"生物医药","399441":"生物医药","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","BK4211":"区域性银行","BK1161":"生物科技","BK4195":"互助储蓄与抵押信贷金融服务","09939":"开拓药业-B","BK1515":"抗疫概念","03347":"泰格医药","BK1574":"生物医药B类股","HCC":"Warrior Met Coal LLC","ORR":"Militia Long/Short Equity ETF","BK1583":"高瓴概念","BK4006":"钢铁","02256":"和誉-B","PFS":"Provident Financial Services Inc","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"[Heyu-B (02256. HK): Heyu Pharmaceuticals will report on the combination of epagotinib and atezolizumab in the treatment of advanced hepatocellular carcinoma at the ESMO GI meeting in 2025","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"161726":1,"399441":1,"PFS":1,"03347":1,"HCC":1,"02256":1,"09939":1,"ORR":1},"content_text":"【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌的最新2期临床试验数据】智通财经APP讯，和誉-B(02256.HK)发布公告，2025年6月26日，上海和誉生物医药科技有限公司(“和誉医药”)宣布将在2025 \n\n年欧洲肿瘤内科学会胃肠道肿瘤大会(“2025年ESMO \n\nGI会议”)上汇报依帕戈替尼(Irpagratinib/ABSK-011)与阿替利珠单抗联用治疗晚期肝细胞癌(“HCC”)患者的最新2期临床试验数据。2025年ESMO \n\nGI会议将于2025年7月2日至2025年7月 \n\n5日(当地时间)在西班牙巴塞罗那举行。本次口头汇报显示，依帕戈替尼与阿替利珠单抗联合治疗方案在未接受治疗及既往接受过治疗的FGF19过表达HCC患者中，均展现出良好的安全性与显着的疗效。依帕戈替尼联用显示达到客观缓解率(“ORR”)≥50%，中位无进展生存期(“PFS”)≥7个月。这些结果进一步证明了依帕戈替尼在既往接受过治疗和未接受治疗情况下的临床益处，为晚期HCC患者带来了新的希望。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2546227969","isCrawlerRequest":true}